Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fera Diagnostics And Biologicals Corp. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner and 1 distinct art unit. The portfolio's current activity is focused on this 1 pending matter. Practitioners should note that the 1 distinct art unit involved indicates a specialized focus within the biotechnology field. The concentration of the portfolio means that the company's immediate patent strategy is concentrated on 1 point of contact within the patent office. This allows for a targeted approach to prosecution.
The busiest examiner is CHONG, YONG SOO, who is responsible for 1 pending office action. Because there is 1 pending office action in total, this 1 examiner is the only one currently reviewing applications for the company. The results of this 1 prosecution will determine the company's immediate success in this technology area. This centralization means that the company's immediate patent prospects are entirely subject to the review and requirements of this 1 individual. Building a clear and persuasive record with CHONG, YONG SOO is the primary task for the company's current prosecution efforts. Practitioners can focus exclusively on the preferences of this 1 examiner to advance the 1 pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19535590 | FATTY ACID COMPOSITIONS | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19535590 | FATTY ACID COMPOSITIONS | CHONG, YONG SOO | 1623 | §102 | Final Rejection | — | Pending | Feb 10, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFera Diagnostics And Biologicals Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yong Soo Chong has the most, with 1 of Fera Diagnostics And Biologicals Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
